[go: up one dir, main page]

DK1265615T3 - Ny kombination af ikkesederende antihistaminika med substanser, der påvirker leukotrien-virkningen, til behandling af rhinitis/conjunctivtis - Google Patents

Ny kombination af ikkesederende antihistaminika med substanser, der påvirker leukotrien-virkningen, til behandling af rhinitis/conjunctivtis

Info

Publication number
DK1265615T3
DK1265615T3 DK01911591T DK01911591T DK1265615T3 DK 1265615 T3 DK1265615 T3 DK 1265615T3 DK 01911591 T DK01911591 T DK 01911591T DK 01911591 T DK01911591 T DK 01911591T DK 1265615 T3 DK1265615 T3 DK 1265615T3
Authority
DK
Denmark
Prior art keywords
conjunctivitis
rhinitis
treatment
new combination
substances affecting
Prior art date
Application number
DK01911591T
Other languages
Danish (da)
English (en)
Inventor
Hildegard Kuss
Juergen Engel
Istvan Szelenyi
Original Assignee
Viatris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viatris Gmbh filed Critical Viatris Gmbh
Application granted granted Critical
Publication of DK1265615T3 publication Critical patent/DK1265615T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK01911591T 2000-02-17 2001-02-05 Ny kombination af ikkesederende antihistaminika med substanser, der påvirker leukotrien-virkningen, til behandling af rhinitis/conjunctivtis DK1265615T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10007203A DE10007203A1 (de) 2000-02-17 2000-02-17 Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
PCT/EP2001/001190 WO2001060407A2 (fr) 2000-02-17 2001-02-05 Nouvelle combinaison d'antihistaminiques non sedatifs et de substances qui influencent l'effet du leucotriene, pour le traitement de la rhinite/conjonctivite

Publications (1)

Publication Number Publication Date
DK1265615T3 true DK1265615T3 (da) 2005-05-30

Family

ID=7631276

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01911591T DK1265615T3 (da) 2000-02-17 2001-02-05 Ny kombination af ikkesederende antihistaminika med substanser, der påvirker leukotrien-virkningen, til behandling af rhinitis/conjunctivtis

Country Status (26)

Country Link
US (1) US6436924B2 (fr)
EP (1) EP1265615B1 (fr)
JP (1) JP5529362B2 (fr)
KR (1) KR100764329B1 (fr)
CN (1) CN1241569C (fr)
AR (1) AR027528A1 (fr)
AT (1) ATE287266T1 (fr)
AU (1) AU781177B2 (fr)
BR (1) BR0108445A (fr)
CZ (1) CZ296395B6 (fr)
DE (2) DE10007203A1 (fr)
DK (1) DK1265615T3 (fr)
ES (1) ES2236189T3 (fr)
HU (1) HU228927B1 (fr)
IL (2) IL151106A0 (fr)
MX (1) MXPA02008064A (fr)
NO (1) NO328153B1 (fr)
NZ (1) NZ520470A (fr)
PL (1) PL198357B1 (fr)
PT (1) PT1265615E (fr)
RU (1) RU2292208C2 (fr)
SK (1) SK285990B6 (fr)
TW (1) TWI296525B (fr)
UA (1) UA72587C2 (fr)
WO (1) WO2001060407A2 (fr)
ZA (1) ZA200206575B (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2373186A (en) * 2001-02-23 2002-09-18 Astrazeneca Ab Pharmaceutical combinations of a CCR3 antagonist and a compound which is usefulreatment of asthma, allergic disease or inflammation
FR2833493B1 (fr) * 2001-12-18 2005-09-23 Ioltechnologie Production Forme galenique solide et soluble pour l'administration occulaire de principes actifs et procede de fabrication d'un insert ophtalmique solide et soluble
WO2003101434A2 (fr) * 2001-12-21 2003-12-11 Sampad Bhattacharya Compositions pharmaceutiques intranasales comprenant un antihistaminique et un inhibiteur de leucotrienes
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
AU2003301305A1 (en) * 2002-10-17 2004-05-04 Decode Genetics Ehf. Susceptibility gene for myocardial infarction; methods of treatment
US7851486B2 (en) 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
US7507531B2 (en) 2002-10-17 2009-03-24 Decode Genetics Chf. Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
US20040198743A1 (en) * 2003-01-31 2004-10-07 Schering Corporation Methods for treating allergic skin and allergic ocular conditions using combinations of histamine receptor antagonists
US20040235807A1 (en) * 2003-05-21 2004-11-25 Weinrich Karl P. Formulations including a topical decongestant and a topical corticosteroid suitable for nasal administration and method for treating obstructive sleep apnea
CA2539276A1 (fr) * 2003-09-17 2005-03-31 Decode Genetics Ehf. Methodes de prevention ou de traitement de la recurrence de l'infarctus du myocarde
WO2005030331A1 (fr) * 2003-09-26 2005-04-07 Fairfield Clinical Trials, Llc Traitement antihistaminique combine
US20060263350A1 (en) * 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
US8158362B2 (en) 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
CN101518532A (zh) * 2004-02-06 2009-09-02 Meda制药有限及两合公司 用于呼吸道疾病治疗的抗胆碱能药和4型磷酸二酯酶抑制剂的组合
PT1713473E (pt) * 2004-02-06 2013-05-13 Meda Pharma Gmbh & Co Kg Combinação de anticolinérgicos e glucocorticóides para o tratamento a longo prazo de asma e copd
PE20060484A1 (es) * 2004-07-14 2006-07-06 Ucb Farchim Sa Preparaciones farmaceuticas liquidas que comprenden un compuesto de benzhidril piperizina
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
LT2377557T (lt) 2004-11-24 2017-02-10 Meda Pharmaceuticals Inc. Kompozicijos, apimančios azelastiną, ir jų panaudojimo būdai
CN101128196B (zh) * 2005-03-16 2013-01-02 Meda制药有限及两合公司 用于治疗呼吸系统疾病的抗胆碱能药和白三烯受体拮抗剂的组合
US7405302B2 (en) * 2005-10-11 2008-07-29 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
NZ568349A (en) 2005-12-21 2011-05-27 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-agonists, PDE 4 inhibitor and antileukotriene for the treatment of inflammatory diseases
WO2007126865A2 (fr) * 2006-03-30 2007-11-08 Patrin Pharma Administration nasale d'antagonistes de leukotriènes
US20100068301A1 (en) 2006-11-30 2010-03-18 Hutchinson John H Compositions and treatments comprising 5-lipoxygenase-activating protein inhibitors and nitric oxide modulators
ATE534390T1 (de) * 2007-11-19 2011-12-15 Bausch & Lomb Verwendung von levocabastin zur modulierung der erzeugung von proinflammatorischen zytokinen
JP2012520880A (ja) * 2009-03-17 2012-09-10 アーシエックス セラピューティックス， インコーポレイテッド ケトチフェンの眼科用製剤および使用方法
US8569273B2 (en) 2009-03-17 2013-10-29 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
PT2408453T (pt) 2009-03-17 2022-04-05 Nicox Ophthalmics Inc Formulações oftálmicas de cetirizina e métodos de utilização
EP4008327A1 (fr) 2009-04-29 2022-06-08 Amarin Pharmaceuticals Ireland Limited Compositions pharmaceutiques comprenant de l'epa et un agent cardiovasculaire et leurs procédés d'utilisation
KR101418404B1 (ko) * 2012-01-06 2014-07-10 한미약품 주식회사 레보세티리진 또는 이의 약학적으로 허용가능한 염 및 몬테루카스트 또는 이의 약학적으로 허용가능한 염을 함유하는 안정한 경구투여용 약학 제제
WO2014164299A1 (fr) 2013-03-13 2014-10-09 Inflammatory Response Research, Inc. Utilisation de levocetirizine et de montelukast dans le traitement des maladies auto-immunes
KR101943490B1 (ko) 2013-03-13 2019-04-17 플랫틀리 디스커버리 랩, 엘엘씨 피리다지논 화합물 및 낭성 섬유증을 치료하는 방법
KR101555908B1 (ko) * 2013-12-19 2015-09-25 한미약품 주식회사 몬테루카스트 또는 이의 약제학적으로 허용 가능한 염을 포함하는 액상 제제 및 이의 제조방법
US10080748B2 (en) 2014-02-04 2018-09-25 Bioscience Pharma Partners, Llc Use of flap inhibitors to reduce neuroinflammation mediated injury in the central nervous system
JP2017526728A (ja) 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト
KR20210123321A (ko) * 2019-01-11 2021-10-13 내기스 파마슈티컬스 인코포레이티드 류코트리엔 합성 억제제
EP3930642B1 (fr) 2019-02-28 2023-10-25 Coloplast A/S Patch de capteur destiné à être fixé à une plaque de base
CN110721189A (zh) * 2019-11-19 2020-01-24 贵州云峰药业有限公司 一种皮肤消毒剂
US12233055B2 (en) 2020-02-03 2025-02-25 Taro Pharmaceutical Industries Ltd. Topical Montelukast formulations
NZ790643A (en) 2020-02-03 2023-05-26 Taro Pharma Ind Topical montelukast formulations
CN116284470B (zh) * 2023-02-15 2024-08-02 广西中医药大学 一种海蛇尾多糖硫酸酯衍生物的制备方法及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3813384A (en) 1972-01-17 1974-05-28 Asta Werke Ag Chem Fab Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof
EP0316633B1 (fr) 1987-11-13 1993-01-27 ASTA Medica Aktiengesellschaft Médicaments pour l'application dans le nez et/ou à l'oeil contenant de l'azélastine
WO1989010143A1 (fr) * 1988-04-27 1989-11-02 Schering Corporation Certaines combinaisons d'antagonistes/antihistamines de paf (facteur d'activation plaquettaire) et procedes
US5276044A (en) * 1991-08-14 1994-01-04 Allergan, Inc. Leukotriene receptor antagonist and antihistamine complex pharmaceutical compositions
EP1214937B1 (fr) * 1992-08-03 2007-05-30 Sepracor Inc. Le carboxylate de la terfénadine et le traitement de l'irritation de la peau
SK105698A3 (en) * 1996-02-08 1999-05-07 Merck & Co Inc Method of treatment and pharmaceutical composion
DE19610882A1 (de) * 1996-03-20 1997-09-25 Dresden Arzneimittel Neue 1,3,5-trisubstituierte Indazol-Derivate mit antiasthmatischer, antiallergischer, entzündungshemmender und immunmodulierender Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5900421A (en) * 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
AU6878098A (en) * 1997-04-30 1998-11-24 Warner-Lambert Company Topical nasal antiinflammatory compositions
US6242179B1 (en) 1997-12-17 2001-06-05 Incyte Pharmaceuticals, Inc. Human phosphatases
KR100737710B1 (ko) * 1997-12-23 2007-07-11 쉐링 코포레이션 하나 이상의 류코트리엔 길항제와 데스카보에톡실로라티딘를 포함하는 호흡기 질환 및 피부 질환 치료용 조성물
US6194431B1 (en) * 1998-04-14 2001-02-27 Paul D. Rubin Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors

Also Published As

Publication number Publication date
SK285990B6 (sk) 2008-01-07
IL151106A0 (en) 2003-04-10
ATE287266T1 (de) 2005-02-15
EP1265615B1 (fr) 2005-01-19
ES2236189T3 (es) 2005-07-16
TWI296525B (en) 2008-05-11
PL355818A1 (en) 2004-05-17
SK11752002A3 (sk) 2002-11-06
MXPA02008064A (es) 2004-04-05
AR027528A1 (es) 2003-04-02
IL151106A (en) 2008-06-05
JP2003522803A (ja) 2003-07-29
NO20023818L (no) 2002-08-12
DE50105126D1 (de) 2005-02-24
ZA200206575B (en) 2003-05-14
AU781177B2 (en) 2005-05-12
AU4058401A (en) 2001-08-27
CN1400903A (zh) 2003-03-05
RU2002123345A (ru) 2004-03-20
JP5529362B2 (ja) 2014-06-25
RU2292208C2 (ru) 2007-01-27
HK1053792A1 (en) 2003-11-07
US20010025040A1 (en) 2001-09-27
CZ296395B6 (cs) 2006-03-15
NZ520470A (en) 2004-05-28
PT1265615E (pt) 2005-05-31
HUP0204079A3 (en) 2006-07-28
WO2001060407A3 (fr) 2002-03-07
PL198357B1 (pl) 2008-06-30
CN1241569C (zh) 2006-02-15
HUP0204079A2 (hu) 2003-04-28
WO2001060407A2 (fr) 2001-08-23
DE10007203A1 (de) 2001-08-23
US6436924B2 (en) 2002-08-20
EP1265615A2 (fr) 2002-12-18
NO20023818D0 (no) 2002-08-12
KR100764329B1 (ko) 2007-10-05
CZ20022700A3 (cs) 2002-11-13
KR20020083161A (ko) 2002-11-01
BR0108445A (pt) 2003-04-01
UA72587C2 (uk) 2005-03-15
NO328153B1 (no) 2009-12-21
HU228927B1 (en) 2013-06-28

Similar Documents

Publication Publication Date Title
DK1265615T3 (da) Ny kombination af ikkesederende antihistaminika med substanser, der påvirker leukotrien-virkningen, til behandling af rhinitis/conjunctivtis
DK1343773T3 (da) Thiazolderivater til behandling af PPAR-beslægtede forstyrrelser
DK1620437T3 (da) 5,7-diaminopyrazolo-4,3-d-pyrimidiner, der er anvendelige til behandling af hypertension
DK1488180T3 (da) Fremgangsmåde til tørring af vandige fluider med højt lactoseindhold
DK1144395T3 (da) 2-amino-benzoxazinon-derivater til behandling af fedme
NO20042576L (no) Nikotin, eller isonikotinbenzotiazolderivater
DK1196172T3 (da) (S,S)-reboxetin til behandling af kronisk smerte
NO20040072L (no) Nye substituerte benzimidazol-doseringsformer og fremgangsmate for anvendelse av samme
DK1427437T3 (da) Oxyntomodulin til forebyggelse eller behandling af overvægt
DK1143977T3 (da) 2-oxy-benzoxazinonderivater til behandling af obesitas
DK1803718T3 (da) 4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter
DK1063990T3 (da) Anvendelse af Biochanin-beriget ekstrakt til behandling af östrogen-associerede lidelser
NO20042140L (no) Terapeutiske quionolonforbindelser med 5-HT anatagonistiske egenskaper
DK1231920T3 (da) Anvendelse af epinastin til behandling af allergisk rhinitis/conjunctivitis
DK1373256T3 (da) CCR5-antagonister, der er nyttige til behandling af AIDS
DK1392318T3 (da) 15-keto-prostaglandiner til behandling af lægemiddelinduceret forstoppelse
DK1491212T3 (da) Middel til behandling af søvnforstyrrelser
DE60206429D1 (de) Kälte- oder Wärme-Gerät der Absorptionsart
NO20034434L (no) Indolinoner substituert i 6-stilling og deres anvendelse som kinase-inhibitorer
DK1197485T3 (da) Cyclobutendionderivater til behandling af artherosclerose
NO20053348D0 (no) Farmasoytisk sammensetning for behandling av virusangrep.
HRP20080447T3 (en) 7-(2-(4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydro-pyrid-1-yl)ethyl) isoquinoline besylate salt, preparation and therapeutic use thereof
DK1257278T3 (da) Anvendelse af mirtazapin til behandling af sövnforstyrrelser
NO20042613L (no) Ny anvendelse for behandling av gastroosofagial refluks
NO20024352D0 (no) Trinnvis alkylering av 5-substituerte 1-(4-fluorfenyl)-1,3- dihydroisobenzofuraner